Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

SYDNEY, July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus...

Articles similaires

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy

entrepreneur.ca - 13/Aug 03:04

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Tryptamine...

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

financialpost.com - 20/Aug 11:01

Health consequences of over active xanthine oxidase may accelerated PKD progression CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) — XORTX...

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

drugs.com - 12/Aug 01:08

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late...

Long Shortz with Tryptamine Therapeutics: Fantastic fibromyalgia results off the back of US psychedelic trial

stockhead.com.au - 13/Aug 19:55

Tryptamine Therapeutics' (ASX:TYP) Jason Carroll joins Sarah Hughan on Stockhead TV to talk about its drug trial to treat fibromyalgia. ...

India's First Dengue Vaccine on Its Way! Phase III Clinical Study Initiated

medindia.net - 20/Aug 18:16

Indian Council of Medical Research (ICMR) and Panacea Biotec declared the start of Phase III clinical trial for India's first dengue vaccine.

PharmaDrug Joint Venture Receives Approval For Phase 1 Clinical Trial

thedeepdive.ca - 19/Aug 13:08

Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study...

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

drugs.com - 15/Aug 00:08

BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...

Enrollment Completed for Phase 2 Clinical Trial Evaluating VG081821AC for the Treatment of Parkinson's Disease

drugs.com - 18/Aug 22:08

HANGZHOU, China, Aug. 15, 2024. Vimgreen Pharmaceuticals, a science-driven pharmaceutical company focused on the modulation of adenosine signaling,...

Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome

drugs.com - 15/Aug 00:08

MELBOURNE, Australia, Aug. 14, 2024. Prota Therapeutics Pty Ltd (Prota), an Australian clinical-stage biotechnology company focused on the development...

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

drugs.com - 20/Aug 02:08

NEW YORK & MAINZ, Germany--(BUSINESS WIRE) August 16, 2024 -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX,...

Les derniers communiqués

Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022

Rubriques :

Articles similaires

Les derniers communiqués